cDNA-AFLP®

Gene Expression Profiling

The cDNA-AFLP technology permits the display and quantification of transcripts based on AFLP fingerprinting of double-stranded cDNA. The transcript profiles obtained using this technique, are a reliable and efficient tool for the identification of differentially expressed mRNAs.

How it works

The fingerprinting procedure consists of the following steps:

  • isolation of mRNA from the samples of interest;
  • reverse transcription of mRNA using an oligo-dT primer to produce cDNA;
  • digestion of double stranded cDNA with a pair of restriction enzymes;
  • ligation of adapters specific for the two restriction sites;
  • pre-amplification of fragments with primers specific to the two adapter sequences;
  • selective amplification with adapter specific primer combinations with nucleotide extensions at their 3’ ends (usually varying between 1 and 3 selective nucleotides);
  • visualization of individual fragments on a polyacrylamide gel (using radioactive gels: one of the two primers is end labeled with 33P);
  • Analysis by image-processing software. This software identifies the cDNA-AFLP fragments and quantifies the intensities that correspond to the original expression level.

Figure 1. An example and a detail of a cDNA-AFLP fingerprint that shows up and down regulation as well as constant expression in two samples.

Benefits

  • it can visualize over 90% of all expressed genes;
  • no require prior knowledge of the genetic sequence necessary of the analyzed organism / genes;
  • since it is PCR based, it is very sensitive and can detect down to 1 mRNA molecule per cell;
  • bands corresponding to genes / expression profiles of interest can be excised and sequenced;
  • in case the sequence of relevant genes is known, the fragment size and gel position of the resulting cDNA-AFLP fragments can be predicted. As such the gene expression of known genes can be specifically followed.

Applications

  • Gene Expression Profiling;
  • Biomarker Identification;
  • Promoter Identification;
  • Targeted EST Sequencing.
More info

Herco van Liere

Vice-President Business Development
Europe & Asia
T +31 (0)317 466 866